Drug Patents owned by Esperion Theraps Inc
1. List of Nexletol drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(2 years from now) | |
| US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(17 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 21, 2025 |
Drugs and Companies using BEMPEDOIC ACID ingredient
NCE-1 date: 2024-02-22
Market Authorisation Date: 21 February, 2020
Treatment: Use of nexletol as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...
Dosage: TABLET;ORAL
NEXLETOL family patents
25
United States
3
Spain
3
European Union
2
Mexico
2
Hungary
2
Japan
1
Canada
1
Cyprus
1
Slovenia
1
Brazil
1
Australia
1
Denmark
1
Portugal
2. List of Nexlizet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(2 years from now) | |
| US11613511 | ESPERION THERAPS INC | Methods of making bempedoic acid and compositions of the same |
Jun, 2040
(17 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(6 months from now) | |
| US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 21, 2025 |
| New Product (NP) | Feb 26, 2023 |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
NCE-1 date: 2024-02-22
Market Authorisation Date: 26 February, 2020
Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular dise...
Dosage: TABLET;ORAL
NEXLIZET family patents
31
United States
4
Japan
4
European Union
3
Australia
3
Spain
3
Mexico
2
Canada
2
Singapore
2
Russia
2
Brazil
2
China
2
Hungary
1
Korea, Republic of
1
Denmark
1
Chile
1
Cyprus
1
Portugal
1
Ukraine
1
Philippines
1
Morocco
1
Slovenia
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic